Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

MC, Genovese; A, Covarrubias; G, Leon; E, Mysler; M, Keiserman; R, Valente; P, Nash; JA, Simon-Campos; W, Porawska; J, Box; C 3rd, Legerton; E, Nasonov; P, Durez; R, Aranda; R, Pappu; I, Delaet; J, Teng; R, Alten

doi:10.1002/art.30463

Public

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

Shared by NobleBlocks on Oct 1, 2011 • 12:00 AM UTC

Authors:

Genovese MC

Covarrubias A

Leon G

Abstract

<h4>Objective</h4>To compare the efficacy and safety of subcutaneous (SC) and intravenous (IV) abatacept.<h4>Methods</h4>In this phase IIIb double-blind, double-dummy, 6-month study, patients with rheumatoid arthritis (RA) and inadequate responses to methotrexate were randomized to receive 125 mg SC...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!